Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVISE trial of adalimumab versus conventional immunosuppression for non-infectious uveitis
2019-002366-12Phase 3Unknown
- Sponsor
- Johns Hopkins University
- Start
- Oct 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of adalimumab, azathioprine, methotrexate, mycophenolate mofetil, cyclosporine and 2 more in noninfectious uveitis (NIU), Hyalitis, posterior uveitis and 1 more (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Corticosteroid-sparing treatment success. Status: unknown.
02
Drugs
03
Conditions
noninfectious uveitis (NIU)Hyalitisposterior uveitispanuveitis
Beyond the preview
Go deeper on 2019-002366-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002366-12.